BPTH: Bio-Path Holdings Price/Earnings to Growth Ratio

Bio-Path Holdings (BPTH) management's frugal approach to intellectual property development is reflected in the price action, where the PEG ratio change demonstrates the current value of the 0.00 metric. The business foundation is based on liposomal drug delivery methods that guarantee high margins. The professional image of Bio-Path Holdings (BPTH) and hematologists' confidence in antisense therapy sustain steady interest in clinical trials.

Bio-Path Holdings - BPTH Price/Earnings to Growth Ratio (period 07/04/2022 - 03/01/2025)

Analytical breakdowns for Bio-Path Holdings (BPTH)

- share price and consensus valuation forecast:

Price Performance Chart Bio-Path Holdings Inc.|BPTH - Analyst Consensus Forecast

- market capitalization information:

Market Value Bio-Path|BPTH - Total Company Value

- issuer book value statistics:

Net Assets per Single Share Bio-Path Holdings|BPTH - Company Book Value|Market-to-Book Ratio biopathholdings.com|BPTH - Aggregate Company Assets

- issuer credit burden and liquidity indicators:

- financial results and valuation multiples details:

BPTH - Net Income|Projected Net Profit Bio-Path Holdings|BPTH - Price to Earnings Ratio|Price to Expected Earnings Ratio Bio-Path Holdings, Inc|BPTH - PEG Multiple|EV/EBITDA Multiple Bio-Path|BPTH - Operating profit before deduction of amortization|Earnings per share for the last four quarters Bio-Path Holdings|BPTH - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months biopathholdings.com|BPTH - Net earnings per share growth this year|Expected earnings per share trend next year Bio-Path Holdings

General company analysis:Bio-Path Holdings Inc. BPTH

Mass-produced product of Bio-Path Holdings Inc.

By utilizing the DNAbilize platform to combat leukemias, Bio-Path Holdings (BPTH) is developing a product with highly inelastic demand, ensuring significant future pricing power. An analysis of the peg_co ratio allows for the correlation of the current P/E market multiple with earnings growth rates, revealing the asset is undervalued at levels below one and confirming the company's fundamental attractiveness at a cyclical turning point.

Competing companies